Because of the frequent use of L-tryptophan (L-Trp) in dietary supplements, determination of the no-observed-adverse-effectlevel is desirable for public health purposes. We therefore assessed the no-observed-adverse-effect-level for L-Trp and attempted to identify a surrogate biomarker for excess L-Trp in healthy humans. A randomized, double-blind, placebocontrolled, crossover intervention study was performed in 17 apparently healthy Japanese women aged 18-26 y with a BMI of 
Introduction
The nutritional consequences of deficient intake of the essential amino acid L-tryptophan (L-Trp) have been known for more than 7 decades (1). L-Trp plays a critical role in preventing nicotinamide (Nam) 7 deficiency syndrome pellagra, a nutritional disease in humans caused by protein malnutrition (2) . Indeed, pellagra remains a public health problem in many maize-consuming African and Asian countries, especially in emergency-and conflict-affected populations (3) (4) (5) (6) (7) (8) (9) . Free L-Trp is a more efficient precursor of Nam than L-Trp in protein form (10, 11) . Moreover, L-Trp is one of the limiting amino acids in populations of developing countries with low socio-economic status, where the nutritional requirements for L-Trp (300 mg/d in adults) (12) are often unmet. In more developed countries, L-Trp is frequently ingested as a dietary supplement to improve sleep patterns, mental health, and clinical diseases (13) (14) (15) (16) (17) . Although these individuals may be at risk for excessive L-Trp dietary supplementation, to our knowledge, there are no reliable human data on a tolerable upper intake of this amino acid. We therefore sought to determine an interim no-observed-adverse-effect-level of L-Trp in healthy humans ingesting up to 5.0 g/d L-Trp supplements (18) . We also sought to identify a surrogate biomarker for preventing and predicting L-Trp toxicity in humans by measuring the concentrations of the serotonin [5-hydroxytryptamin (5-HT)] and kynurenine (Kyn) metabolites of L-Trp following L-Trp ingestion. Supplemental Figure 1 shows the degradation pathway of L-Trp.
Methods
This study, conducted from September 2010 to October 2011, was reviewed and approved by the Ethical Committee of The University of Shiga Prefecture. All participants provided written informed consent.
Chemicals. Pharmaceutical grade L-Trp was provided by Ajinomoto. 5-HT creatinine sulfate, Nam, pyridoxal 5#-phosphate (PLP), riboflavin, 1 Supported by The International Council on Amino Acid Science Research Funding [to the project entitled ''Development of an index of metabolic upper intake level instead of tolerable upper intake level of tryptophan for humans'' (principal investigator, Katsumi Shibata), of which this study was a part]. This work is a publication of the Department of Food Science and Nutrition, School of Human Cultures, The University of Shiga Prefecture. 2 Author disclosures: C. Hiratsuka, T. Fukuwatari, M. Sano, K. Saito, S. Sasaki, and K. Shibata, no conflicts of interest. 3 Supplemental Figure 1 and Supplemental Tables 1-6 are available through the "Online Supporting Material" link in the online posting of the article and the online table of contents at http://jn.nutrition.org.
* To whom correspondence should be addressed. E-mail: kshibata@shc.usp.ac. jp. 7 Abbreviations used: AnA, anthranilic acid; KA, kynurenic acid; Kyn, kynurenine; LNAA, large neutral amino acid; MNA, N 1 -methylnicotinamide; Nam, nicotinamide; PLP, pyridoxal 5#-phosphate; POMS, profile of mood states; QA, quinolinic acid; TDO, tryptophan 2,3-dioxygenase; XA, xanthurenic acid; 2-OAA, 2-oxoadipic acid; 2-Py, N 1 -methyl-2-pyridone-5-carboxamide; 3-HA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine; 4-PIC, 4-pyridoxic acid; 4-Py, N 1 anthranilic acid (AnA), 3-hydroxykynurenine (3-HK), quinolinic acid (QA), and 2-oxoadipic acid (2-OAA) were purchased from Wako Pure Chemical Industries. 4-Pyridoxic acid (4-PIC) manufactured by ICN Pharmaceuticals was obtained from Wako Pure Chemical Industries. Kyn sulfate, xanthurenic acid (XA), kynurenic acid (KA), 3-hydroxyanthranilic acid (3-HA), and N 1 -methylnicotinamide (MNA) chloride were obtained from Tokyo Kasei Kogyo. 5-Hydroxyindole-3-acetic acid (5-HIAA) was purchased from Sigma-Aldrich Chemicals. N 1 -Methyl-2-pyridone-5-carboxamide (2-Py) (19) and N 1 -methyl-4-pyridone-3-carboxamide (4-Py) (20) were synthesized as described. All other chemicals were of the highest commercially available purity.
Subjects. Female Japanese university students were recruited from The University of Shiga Prefecture. The purpose and protocol of this study were explained to all participants and written informed consent was obtained. Participants diagnosed with cold or influenza and those who had taken multi-vitamin supplements at least once during the previous month were excluded. All participants passed the regular medical examination in the university. Of the 21 apparently healthy female Japanese students who participated in this study, 17 participants aged 18-26 y (means 6 SDs = 20.2 6 0.6 y) completed the study.
Study design. In this randomized, double-blind, placebo-controlled, crossover intervention study, participants were assigned to receive 0 (placebo), Table 1 . Table 2 On the last day of each trial, 24-h urine samples were collected from each participant as well as 30 mL of blood from the arm vein before breakfast (0730 to 0800 h). On the same day, each subject was administered the profile of mood states (POMS) test before lunch at 1200 h.
Each participant selected her own food at all meals and was allowed to submit digital pictures of all food and L-Trp tablets ingested. Intake of nutrients was calculated using a self-administered comprehensive diet history questionnaire (21, 22) .
All trials started at 0900 on d 1 and ended at 0900 on d 22.
General biomarkers in blood. Whole blood samples were sent to the Institute of Shiga Health Center (Shiga, Japan) for measurements of general biomarkers in blood. The hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, number of erythrocyte, and the numbers of types of leukocyte were analyzed by using an XE-2100 automated hematology analyzer (Sysmex Amino acid analysis. Amino acid concentrations in plasma and urine were measured as described (37) .
Statistical analyses.
A power analysis showed that a sample of 19 participants would enable us to detect a medium effect size (f = 0.25) at a power level of 0.8. Twenty-one individuals were recruited to allow for a 10% dropout. Seventeen of 21 participants completed the intervention study, and the actual power level was 0.78.
To examine the dose-response effects of L-Trp administration, a nonparametric Friedman test for repeated measures followed by DunnÕs post hoc test was used to analyze statistical differences among all treatments (Figs. 1 and 2; Tables 3-5; Supplemental Tables 1-6 ). To compare the response of 5.0 g/d L-Trp loading on urinary amounts of 3-HK in the 3 groups (low 3-HK, middle 3-HK, and high 3-HK), a nonparametric Kruskal-Wallis test followed by DunnÕs post hoc test was used to analyze differences among all groups ( Table 6 ). For statistical analysis of Table 7 , the same method of Figs. 1 and 2, Tables 3-5, and  Supplemental Tables 1-6 was applied. P < 0.05 was considered significant. Pearson correlation coefficients were calculated to determine the association between L-Trp intake and the concentration of each 0  0  2 0  0  0  1  4  16  332  996  2  8  12  664  1992  3  12  8  996  2988  4  16  4  1328  3984  5  20  0  1660  4980 860 Hiratsuka et al.
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jn.nutrition.org urinary compound. Graph Pad Prism 5.0 (Graph Pad Software) was used for all statistical analyses.
Results
Characteristics of the subjects and intake of major nutrients and L-Trp The height, body weight, and BMI of the 17 participants were 159.0 6 1.5 cm, 50.8 6 1.6 kg, and 20.1 6 0.3 kg/m 2 , respectively. The body weight of each participant did not change during the course of the study from September 2010 to October 2011, nor did the average daily intake of energy and nutrients (Supplemental Table 1 ). All findings were identical to those previously reported for typical young Japanese women (38) . The usual daily L-Trp intake was a mean of ;700 mg.
General biomarkers in blood and urine
The biomarkers measured in blood and urine are shown in Supplemental Table 2 . None of these variables was affected by the administration of up to 5.0 g/d L-Trp for 21 d. Table 3 shows that administration of up to 5.0 g/d L-Trp for 21 d had no effect on the POMS categories, tension-anxiety, depressiondejection, anger-hostility, vigor, fatigue, and confusion. Blood L-Trp and its metabolites. Table 4 Table 3 ) or of nonproteinaceous amino acids (Supplemental Table 4 ).
POMS test

Urine
Excretion of riboflavin and vitamin B-6. L-Trp administration also had no effect on the urinary excretion of riboflavin and 4-PIC, a major catabolite of vitamin B-6 (Table 5) .
L-Trp and Nam. When we assessed the effect of L-Trp administration on the urinary excretion of L-Trp and Nam, we found that urinary excretion of L-Trp increased relative to the amount of L-Trp ingested (Fig. 1) , whereas the excretion of 5-HIAA remained relatively constant (Table 5 ). We also found that the urinary concentrations of each Nam catabolite, MNA, 2-Py, and 4-Py, as well as their sum, increased in proportion to the amount of L-Trp ingested, whereas the concentration of Nam did not.
Metabolites of the Kyn pathway. We found that the concentrations of the L-Trp metabolites Kyn, AnA, KA, 3-HK, XA, 3-HA, QA, and 2-OAA excreted into the urine increased in proportion to the amount of L-Trp ingested (Fig. 1) . Of these 8 L-Trp metabolites, 3-HK had characteristics of a surrogate biomarker (Fig. 2) . Although, the urinary excretion of 3-HK abruptly increased when the participants were loaded with 5.0 g/d L-Trp, differences among individuals were observed. Relative to the basal concentration of urinary 3-HK excreted by those ingesting a normal concentration of L-Trp (;700 mg/d), participants fell into 3 categories in response to 5.0 g/d L-Trp loading: high responders (329-fold; n = 6) ( Fig. 2A) , moderate responders (46-fold; n = 6) (Fig. 2B) , and low responders (15-fold; n = 5) (Fig. 2C) . When we compared the concentrations of the other L-Trp metabolites in these 3 groups, we observed no differences in the urinary concentrations of Kyn, AnA, KA, XA, 3-HA, QA, and 2-OAA as well as L-Trp itself (Table 6) . Table 7 shows the calculated percentages of urinary L-Trp metabolites relative to L-Trp intake. Only the percentage of 3-HK increased in proportion to the amount of L-Trp ingested.
Amino acids. The amount of L-Trp ingested did not affect the urinary excretion of amino acids contained in proteins (Supplemental Table 5 ) or nonproteinaceous amino acids (Supplemental Table 6 ).
Discussion
L-Trp loading has been reported to mildly alleviate insomnia, depression, sleep disorders, headaches, and clinical diseases (13) (14) (15) (16) (17) , most probably via serotogenic stimulation and Kyn metabolites. Administration of as little as 3.0 g L-Trp was found to increase the brain 5-HT concentration 2-fold (39, 40) . Interestingly, we found that administration of up to 5.0 g/d L-Trp had no effect on POMS test scores. The plasma ratio of L-Trp:large neutral amino acids (LNAAs) may be an important parameter of L-Trp adequacy (17) . In healthy participants, plasma L-Trp:LNAA ratio increases of up to 80% did not modulate mood and memory, whereas a ratio >191% was reported to lead to improved mood and attention (41, 42) . We found that L-Trp loading did not affect the L-Trp:LNAA ratio, which may explain the lack of effect of L-Trp loading on tensionanxiety, depression-dejection, anger-hostility, vigor, fatigue, and confusion in our participants. However, blood samples were taken before breakfast on the last day of each trial, whereas POMS tests were administered several hours later, before lunch.
Carbohydrates such as starch, which contain no L-Trp, increase brain L-Trp and 5-HT because of carbohydrate induction of glucose, insulin secretion, and the consequent uptake of LNAA, but not L-Trp, into skeletal muscles (43) . We therefore evaluated the dietary habits of our participants, but we found no correlation between L-Trp loading and dietary habits. In Japan, rice remains the main staple food. The average intake of cooked polished rice during the trials was~250 g/d (data not shown), resulting in a starch intake of~100 g/d. The average amounts of the LNAAs isoleucine, leucine, lysine, phenylalanine, and tyrosine in dietary food were 1.3, 2.3, 2.0, 1.3 and 1.0 g/d, respectively, during the trial periods, whereas the intake of L-Trp was 0.7 g/d. Therefore, under basal conditions, the L-Trp:LNAA ratio in dietary food was 0.089 (0.7:7.9). Participants who Following the ingestion of L-Trp, riboflavin-deficient rats excreted abnormally high amounts of AnA and KA (49, 50) . Kyn monooxygenase is a flavin adenine dinucleotide enzyme that localizes in the outer membrane of the mitochondria (51, 52) , and a riboflavin deficiency decreases the activity of Kyn monooxygenase. The flux from Kyn into 3-HK thus gives rise to the formation of KA and AnA. We found, however, that in response to ingestion of large amounts of L-Trp, the blood riboflavin concentration and urinary excretion of riboflavin, both of which reflect riboflavin nutritional status, were normal. Rats deficient in vitamin B-6 excrete abnormally large amounts of XA (53) after the ingestion of L-Trp. Kynureninase is a PLP enzyme (54) present in the soluble fraction (54) . Vitamin B-6 deficiency reduces the activity of this enzyme. Although Kyn aminotransferase is also a PLP enzyme (55) , its activity is tolerant of vitamin B-6 deficiency, because it is localized in the inner membrane of mitochondria (56) . Thus, in vitamin B-6-deficient rats, Kyn is metabolized to 3-HK, but the conversion of 3-HK to 3-HA, catalyzed by kynureninase, decreases (56) and the accumulated 3-HK is metabolized to XA.
We found that L-Trp loading did not result in deficiencies in riboflavin and vitamin B-6, because their concentrations in blood and urine, as riboflavin and 4-PIC, respectively, did not decrease, even in participants taking 5.0 g/d L-Trp. The average intakes of riboflavin and vitamin B-6 by our participants were 1.2 and 0.8-0.9 mg/d, respectively, both within Japanese Dietary Reference Intakes ranges (38) Ingestion of up to 5.0 g/d L-Trp for 21 d had no adverse effects on our population of young Japanese women. Although apparently safe, the amount may be affected by several factors (58) (59) (60) (61) (62) (63) , suggesting the need for a biomarker preventing and predicting toxicities in response to excess L-Trp. Our findings suggest that urinary 3-HK, a compound easily assayed (28) , is a candidate biomarker for preventing and predicting toxicity in response to excess L-Trp. Future investigations should determine whether urinary excretion of 3-HK is a useful biomarker for preventing and predicting excess L-Trp toxicity. Labeled means in a column without a common letter differ, P , 0.05. AnA, anthranilic acid; KA, kynurenic acid; Kyn, kynurenine; QA, quinolinic acid; XA, xanthurenic acid; 2-OAA, 2-oxoadipic acid; 3-HA, 3-hydroxyanthralinic acid; 3-HK, 3-hydroxykynurenine.
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In conclusion, oral administration of up to 5.0 g/d L-Trp for 3 wk did not cause any adverse effects in young adult females. Therefore, administration of pure L-Trp at doses up to 5.0 g/d may be a suitable nutritional intervention for populations in need, as well as for healthy adults who wish to use L-Trp for nonnutritive purposes. Further testing of higher doses in both females and males may be warranted.
